- Veru Inc VERU reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million.
- FC2 prescription net revenues climbed 55% Y/Y to $13.6 million.
- Gross profit rose 29% to $12.3 million, while the margin contracted 200 basis points Y/Y to 79%.
- The operating loss for the quarter narrowed to $(1.9) million.
- The company held $122.4 million in cash and equivalents as of September 30, 2021.
- EPS loss of $(0.05) beat the analyst consensus of $(0.09).
- Price Action: VERU shares traded lower by 2.32% at $6.75 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
